Filtered By:
Specialty: Drugs & Pharmacology

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 3220 results found since Jan 2013.

Glypican-3 gene silencing for ovarian cancer using siRNA-PLGA hybrid micelles in a murine peritoneal dissemination model
Publication date: Available online 10 February 2019Source: Journal of Pharmacological SciencesAuthor(s): Mai Hazekawa, Takuya Nishinakagawa, Tomoyo Kawakubo-Yasukochi, Manabu NakashimaAbstractSmall interfering RNA (siRNA) has received much attention and for possible therapeutic applications to treat incurable chronic and genetic diseases, including cancer. However, the development of safe and efficient carriers for siRNA delivery still remains formidable hurdles for in vivo. The purpose of this study is to prepare siRNA–PLGA hybrid micelles to deliver the siRNA into the ovarian cancer cells and to evaluate of gene silenc...
Source: Journal of Pharmacological Sciences - February 11, 2019 Category: Drugs & Pharmacology Source Type: research

Lipidoid-Polymer Hybrid Nanoparticles Loaded with TNF siRNA Suppress Inflammation after Intra-articular Administration in a Murine Experimental Arthritis Model.
Abstract Rheumatoid arthritis (RA) is a common autoimmune disease, which is characterized by painful chronic inflammation in the joints, and novel safe and efficacious treatments are urgently needed. RNA interference (RNAi) therapy based on small interfering RNA (siRNA) is a promising approach for silencing specific genes involved in inflammation. However, delivery of siRNA to the target site, i.e. the cytosol of immune cells, is a challenge. Here, we designed lipid-polymer hybrid nanoparticles (LPNs) composed of lipidoid and poly(DL-lactic-co-glycolic acid) loaded with a therapeutic cargo siRNA directed against t...
Source: European Journal of Pharmaceutics and Biopharmaceutics - June 10, 2019 Category: Drugs & Pharmacology Authors: Jansen MAA, Klausen LH, Thanki K, Lyngsø J, Skov Pedersen J, Franzyk H, Nielsen HM, van Eden W, Dong M, Broere F, Foged C, Zeng X Tags: Eur J Pharm Biopharm Source Type: research

Enhanced Cellular Uptake and Gene Silencing Activity of Survivin-siRNA via Ultrasound-Mediated Nanobubbles in Lung Cancer Cells
ConclusionThe ultrasound responsive nanobubble system carrying paclitaxel and survivin-siRNA is a promising and effective approach against lung cancer cells.
Source: Pharmaceutical Research - August 4, 2020 Category: Drugs & Pharmacology Source Type: research

Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics – a Minireview
AbstractThe approval of four small interfering RNA (siRNA) products in the past few years has demonstrated unequivocally the therapeutic potential of this novel modality. Three such products (givosiran, lumasiran and inclisiran) are liver-targeted, using tris N-acetylgalactosamine (GalNAc)3 as the targeting ligand. Upon subcutaneous administration, GalNAc-conjugated siRNAs rapidly distribute into the liver via asialoglycoprotein receptor (ASGPR) mediated uptake in the hepatocytes, resulting in fast elimination from the systemic circulation. Patisiran, on the other hand, has been formulated in a lipid nanoparticle for optim...
Source: Pharmaceutical Research - July 12, 2022 Category: Drugs & Pharmacology Source Type: research

Subretinal transfection of chitosan-loaded TLR3-siRNA for the treatment of experimental autoimmune uveitis.
Abstract The local interaction between retinal pigment epithelium (RPE) and immigrated effector T cells is crucial for the pathogenesis of autoimmune uveitis. After being activated by the pattern recognition receptors (PRRs) signaling pathway, RPE can present the antigen reactivated invading autoreactive T cells, resulting in uveitis. In the present study, we showed that the transfection of chitosan-loaded TLR3-siRNA toward RPE could effectively remit experimental autoimmune uveitis (EAU) in B10RIII mice. Initially, we verified the constitutive expression of Tlr3 in RPE at high levels, which was not altered in the...
Source: European Journal of Pharmaceutics and Biopharmaceutics - September 17, 2013 Category: Drugs & Pharmacology Authors: Chen S, Yan H, Sun B, Zuo A, Liang D Tags: Eur J Pharm Biopharm Source Type: research

Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: For the potential targeted ovarian cancer gene therapy.
Abstract For effective ovarian cancer gene therapy, systemic administrated tumor-targeting siRNA/folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate (FA-PEG-COL) nanoparticles is vital for delivery to cancer site(s). siRNA/FA-PEG-COL nanoparticles were prepared by ionic gelation for effective FA receptor-expressing ovarian cancer cells transfection and in-vivo accumulation. The chemical structure of FA-PEG-COL conjugate was characterized by MALDI-TOF-MS, FT-IR and H(1) NMR. The average size of siRNA/FA-PEG-COL nanoparticles was approximately 200 nm, and the surface charge was +8.4 mV compared to +30....
Source: European Journal of Pharmaceutical Sciences - October 28, 2013 Category: Drugs & Pharmacology Authors: Li TS, Yawata T, Honke K Tags: Eur J Pharm Sci Source Type: research

Inhibition of Cancer Cell Growth by GRP78 siRNA Lipoplex via Activation of Unfolded Protein Response.
Abstract Proteasome inhibitors are a novel class of molecular-targeted anti-cancer drugs that suppress the degradation of malfolded proteins, trigger endoplasmic reticulum (ER) stress, and activate apoptosis signals. Glucose-regulated protein 78 (GRP78), a major ER chaperone, is one of the most important molecules for transduction of unfolded protein response (UPR) signals. In accordance with past findings that expression of GRP78 is elevated in cancer cells and helps to resist stress-induced apoptosis, GRP78 knockdown could be effective in anticancer therapy. We tested this hypothesis and found that transfection ...
Source: Biological and Pharmaceutical Bulletin - April 6, 2014 Category: Drugs & Pharmacology Authors: Matsumura K, Sakai C, Kawakami S, Yamashita F, Hashida M Tags: Biol Pharm Bull Source Type: research

siRNA Technology in Kidney Transplantation: Current Status and Future Potential
Abstract Kidney transplantation is one of the most common transplantation operations in the world, accounting for up to 50 % of all transplantation surgeries. To curtail the damage to transplanted organs that is caused by ischemia–reperfusion injury and the recipient’s immune system, small interfering RNA (siRNA) technology is being explored. Importantly, the kidney as a whole is a preferential site for non-specific systemic delivery of siRNA. To date, most attempts at siRNA-based therapy for transplantation-related conditions have remained at the in vitro stage, with only a few of them being advanced into a...
Source: BioDrugs - August 1, 2014 Category: Drugs & Pharmacology Source Type: research

Co-delivery of siRNA and hypericin into cancer cells by hyaluronic acid modified PLGA-PEI nanoparticles.
CONCLUSION: Results demonstrated that Hy-HPP NPs could significantly enhance the tranfection efficiency of siRNA, suggesting Hy-encapsulated nanoparticle as an efficient gene carrier. The co-delivery of HIF-1α siRNA (siHIF-1α) and Hy could efficiently decrease the level of HIF-1α and increase the affinity toward necrotic tissues. Hence, this is a promising strategy for further application in radiotherapy. PMID: 26472259 [PubMed - as supplied by publisher]
Source: Drug Development and Industrial Pharmacy - February 16, 2016 Category: Drugs & Pharmacology Tags: Drug Dev Ind Pharm Source Type: research

Cyclin D1 Gene Silencing by siRNA in ex vivo human tissue cultures.
CONCLUSION: It is possible to silencing Cyclin D1 expression in vitro "organ culture" model. Our preliminary results encourage further investigations, using different siRNA concentrations delivered by nanoliposomes. PMID: 27174173 [PubMed - as supplied by publisher]
Source: Current Drug Delivery - May 11, 2016 Category: Drugs & Pharmacology Authors: Piazza O, Russo I, Bocchicchio S, Barba AA, Lamberti G, Zeppa P, Di Crescenzo V, Carrizzo A, Vecchione C, Ciacci C Tags: Curr Drug Deliv Source Type: research

Modulated cellular delivery of anti-VEGF siRNA (bevasiranib) by incorporating supramolecular assemblies of hydrophobically modified polyamidoamine dendrimer in stealth liposomes
Publication date: 20 August 2016 Source:International Journal of Pharmaceutics, Volume 510, Issue 1 Author(s): Nasim Golkar, Soliman Mohammadi Samani, Ali Mohammad Tamaddon A novel lipopolymer based system was designed and characterized for cellular delivery of anti-VEGF siRNA in SKBR-3 breast tumor cell line. Polyamidoamine (PAMAM) dendrimers of low generations (G1, G2 and G3) were incorporated into polyethylene glycol (PEG)-stabilized liposomes by following the consecutive steps: (a) synthesis of the cholesterol conjugates (40% molar ratio of cholesterol to primary amines of PAMAM), (b) incorporation of the conjugat...
Source: International Journal of Pharmaceutics - June 17, 2016 Category: Drugs & Pharmacology Source Type: research

Effects of HMGA2 siRNA and doxorubicin dual delivery by chitosan nanoparticles on cytotoxicity and gene expression of HT‐29 colorectal cancer cell line
ConclusionIn conclusion, our results revealed that dual delivery of a key gene siRNA and appropriate anticancer drug have great impact on the treatment of colorectal cancer.
Source: Journal of Pharmacy and Pharmacology - June 27, 2016 Category: Drugs & Pharmacology Authors: Homayoon Siahmansouri, Mohammad Hossein Somi, Zohreh Babaloo, Behzad Baradaran, Farhad Jadidi‐Niaragh, Fatemeh Atyabi, Hamed Mohammadi, Majid Ahmadi, Mehdi Yousefi Tags: Research Paper Source Type: research

Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells
In conclusion, co-delivery of IL17RB siRNA and DOX can be considered as an effective system for the treatment of breast cancer.
Source: Biomedicine and Pharmacotherapy - June 30, 2016 Category: Drugs & Pharmacology Source Type: research

Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat
In conclusion, we demonstrated that siRNA can be efficiently delivered into the rat retina using lipid-based nanocarriers, and some of the lipoplexes loaded with siRNA silencing HuR expression are potential candidates to manage retinal diseases. Graphical abstract
Source: Pharmacological Research - July 27, 2016 Category: Drugs & Pharmacology Source Type: research